Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Gómez Rueda A, Taus Á, Álvarez Álvarez R, Bernabé-Caro R, Chara L, López-Brea M, Vilà L, Sala González MÁ, Del Barrio Díaz Aldagalán A, Esteban Herrera B, López Castro R, Álvarez Cabellos R, Doménech M, Falagan S, Moreno Vega A, Aguado C, Barba A, Delgado Ureña MT, Isla D, Bellido Hernández L, Fírvida Pérez JL, Juan-Vidal Ó, Massutí B, Mielgo-Rubio X, Ortega AL, Catot S, Dómine M, Escoín-Pérez C, García Navalón F, Gil-Bazo I, Muñoz S, Rodríguez-Abreu D, Villatoro Roldán RM, Alonso-Jáudenes Curbera G, León-Mateos L, Padilla A, Paredes Lario A, Sánchez-Torres JM, Garrido P; Spanish Lung Cancer Group. Gómez Rueda A, et al. Among authors: lopez brea m. Clin Transl Oncol. 2024 Mar 21. doi: 10.1007/s12094-024-03404-9. Online ahead of print. Clin Transl Oncol. 2024. PMID: 38512450
Long term results of a phase II trial of induction chemotherapy with uracil-ftegafur (UFT), vinorelbine and cisplatin (UFTVP) followed by radiotherapy concomitant with UFT and carboplatin (RT/UFTJ) in non-resectable locally advanced (stage IV-B) squamous cell head and neck carcinoma and peripheral blood stem cell support (PBSCS) with febrile neutropenia.
Rivera F, Vega-Villegas ME, López-Brea MF, García-Castaño A, de Juan A, Ramos FJ, Collado A, Galdós P, Rubio A, del Valle A, Rama J, Mayorga M, Sanz-Ortiz J. Rivera F, et al. Clin Transl Oncol. 2007 Jan;9(1):40-7. doi: 10.1007/s12094-007-0008-5. Clin Transl Oncol. 2007. PMID: 17272229 Clinical Trial.
Screening for epidermal growth factor receptor mutations in lung cancer.
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group. Rosell R, et al. N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19. N Engl J Med. 2009. PMID: 19692684 Free article.
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F. Conde E, et al. J Thorac Oncol. 2019 Dec;14(12):2120-2132. doi: 10.1016/j.jtho.2019.07.005. Epub 2019 Jul 23. J Thorac Oncol. 2019. PMID: 31349061 Free article.
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology.
Garrido P, Paz-Ares L, Majem M, Morán T, Trigo JM, Bosch-Barrera J, Garcίa-Campelo R, González-Larriba JL, Sánchez-Torres JM, Isla D, Viñolas N, Camps C, Insa A, Juan Ó, Massuti B, Paredes A, Artal Á, López-Brea M, Palacios J, Felip E. Garrido P, et al. Among authors: lopez brea m. Cancer Med. 2021 Sep;10(17):5878-5888. doi: 10.1002/cam4.4135. Epub 2021 Jul 23. Cancer Med. 2021. PMID: 34296539 Free PMC article. Clinical Trial.
PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis.
García Campelo MR, Arriola E, Campos Balea B, López-Brea M, Fuentes-Pradera J, de Castro Carpeno J, Aguado C, Pérez Parente D, de Oro Pulido F, Ruiz-Gracia P, Rodríguez-Abreu D. García Campelo MR, et al. Among authors: lopez brea m. J Clin Med. 2021 Oct 4;10(19):4583. doi: 10.3390/jcm10194583. J Clin Med. 2021. PMID: 34640601 Free PMC article. Review.
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program.
Bernabé-Caro R, Garrido P, García-Campelo R, Palmero R, Artal Á, Bayona C, Rodríguez-Abreu D, López-Brea M, Paredes A, Vicente D, Sánchez Torres JM, Majem M, Diz P, Gordo R, Coca M, de Castro J. Bernabé-Caro R, et al. Among authors: lopez brea m. Oncotarget. 2022 Jun 15;13:812-827. doi: 10.18632/oncotarget.28244. eCollection 2022. Oncotarget. 2022. PMID: 35720977 Free PMC article.
215 results